Related references
Note: Only part of the references are listed.Lichenoid Drug Eruption with Palmoplantar Hyperkeratosis due to Imatinib Mesylate: A Case Report and a Review of the Literature
Natsuki Kuraishi et al.
ACTA DERMATO-VENEREOLOGICA (2010)
Cutaneous Lichenoid Eruption Caused by Imatinib Mesylate in a Japanese Patient with Chronic Myeloid Leukaemia
Tamihiro Kawakami et al.
ACTA DERMATO-VENEREOLOGICA (2009)
Disappearance of Lentigines in a Patient Receiving Imatinib Treatment for Familial Gastrointestinal Stromal Tumor Syndrome
Tracy Campbell et al.
ARCHIVES OF DERMATOLOGY (2009)
Imatinib: a designer drug, another cutaneous complication
E. Dickens et al.
CLINICAL AND EXPERIMENTAL DERMATOLOGY (2009)
Tyrosine Kinase Inhibitors - A Review on Pharmacology, Metabolism and Side Effects
Joerg Thomas Hartmann et al.
CURRENT DRUG METABOLISM (2009)
Imatinib-associated hyperpigmentation, a side effect that should be recognized
T. Mcpherson et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2009)
A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide
I. Sabnani et al.
RHEUMATOLOGY (2009)
Skin and oral lesions associated to imatinib mesylate therapy
Fernanda Goncalves Basso et al.
SUPPORTIVE CARE IN CANCER (2009)
The toxicities of modern targeted therapies-learning from the price of progress
Francis J. Giles
TARGETED ONCOLOGY (2009)
Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials
Jiri Pavlu et al.
CLINICAL LYMPHOMA & MYELOMA (2009)
Bullous Sweet syndrome in a patient with t(9;22)(q34;q11)-positive chronic myeloid leukemia treated with the tyrosine kinase inhibitor nilotinib - Interphase cytogenetic detection of BCR-ABL-positive lesional cells
Kjell Matthias Kaune et al.
ARCHIVES OF DERMATOLOGY (2008)
Is imatinib mesylate a promising drug in systemic sclerosis?
P. L. A. van Daele et al.
ARTHRITIS AND RHEUMATISM (2008)
Imatinib mesylate treatment of nephrogenic systemic fibrosis
Jonathan Kay et al.
ARTHRITIS AND RHEUMATISM (2008)
Dual inhibition of c-abl and PDGF receptor signaling by dasatinib and nilotinib for the treatment of dermal fibrosis
Alfiya Akhmetshina et al.
FASEB JOURNAL (2008)
Chemotherapeutic agents and the skin: An update
Noushin Heidary et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
Intracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosis
J. H. W. Distler et al.
RHEUMATOLOGY (2008)
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Hagop M. Kantarjian et al.
BLOOD (2007)
Tyrosine kinase inhibitors for the treatment of Philadelphia chromosome-positive adult acute lymphoblastic leukemia
Pier Paolo Piccaluga et al.
CANCER (2007)
Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose
Manoranjan Mahapatra et al.
ANNALS OF HEMATOLOGY (2007)
Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy
Andreas Hochhaus et al.
BLOOD (2007)
Heliotrope-like eruption mimicking dermatomyositis in a patient treated with imatinib mesylate for chronic myeloid leukemia
Yoshihiro Kuwano et al.
INTERNATIONAL JOURNAL OF DERMATOLOGY (2006)
Desensitization to imatinib in patients with leukemia
Robert P. Nelson et al.
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY (2006)
Imatinib mesilate inhibits melanogenesis in vitro
M. Cario-Andre et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL
E. Weisberg et al.
BRITISH JOURNAL OF CANCER (2006)
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Moshe Talpaz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
Hagop Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Panniculitis during dasatinib therapy for imatinib-resistant chronic myelogenous leukemia
Sarit Assouline et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Dasatinib-related alveolar pneumonia responsive to corticosteroids
F. Radaelli et al.
LEUKEMIA & LYMPHOMA (2006)
Imatinib-associated lichenoid eruption: acitretin treatment allows maintained antineoplastic effect
J Dalmau et al.
BRITISH JOURNAL OF DERMATOLOGY (2006)
Pityriasis rosea-like eruption during treatment with imatinib mesylate: Description of 3 cases
V Brazzelli et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants
T O'Hare et al.
CANCER RESEARCH (2005)
Imatinib-induced sweet syndrome in a patient with chronic myeloid leukemia
SJ Ayirookuzhi et al.
ARCHIVES OF DERMATOLOGY (2005)
Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance
MR Burgess et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib
M Breccia et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2005)
Neutrophilic eccrine hidradenitis induced by imatinib mesylate (Gleevec) therapy
EG Dib et al.
LEUKEMIA RESEARCH (2005)
Severe pustular eruption associated with imatinib and voriconazole in a patient with chronic myeloid leukemia
E Gambillara et al.
DERMATOLOGY (2005)
Adverse reactions during imatinib and lansoprazole treatment in gastrointestinal stromal tumors
G Severino et al.
ANNALS OF PHARMACOTHERAPY (2005)
Imatinib mesilate (Glivec((R))): a systemic depigmenting agent for extensive vitiligo?
L Legros et al.
BRITISH JOURNAL OF DERMATOLOGY (2005)
Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate
B Arora et al.
ANNALS OF ONCOLOGY (2004)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Follicular mucinosis associated with imatinib (STI571)
T Yanagi et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Reactivation of porphyria cutanea tarda as a possible side effect of Imatinib at high dosage in chronic myeloid leukemia
M Breccia et al.
LEUKEMIA (2004)
Indications for imatinib mesylate therapy and clinical management
F Guilhot
ONCOLOGIST (2004)
EBV-positive cutaneous B-cell lymphoproliferative disease after imatinib mesylate
MW Bekkenk et al.
BLOOD (2003)
Panniculitis in a patient with chronic myelogenous leukaemia treated with imatinib
S Ugurel et al.
BRITISH JOURNAL OF DERMATOLOGY (2003)
Practical management of patients with chronic myeloid leukemia receiving imatinib
MWN Deininger et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Precipitation of porphyria cutanea tarda by imatinib mesylate?
AYL Ho et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Imatinib treatment: Specific issues related to safety, fertility, and pregnancy
ML Hensley et al.
SEMINARS IN HEMATOLOGY (2003)
Mycosis fungoides-like reaction in a patient treated with Gleevec
SH Clark et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2003)
Severe skin reaction to imatinib in a case of Philadelphia-positive acute lymphoblastic leukemia
B Sanchez-Gonzalez et al.
BLOOD (2003)
Photosensitization in chronic myelogenous leukaemia patients treated with imatinib mesylate
P Rousselot et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec®)
A Drummond et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Adverse cutaneous reactions to imatinib (ST1571) in Philadelphia chromosome-positive leukemias: A prospective study of 54 patients
L Valeyrie et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2003)
Imatinib (STI-571)-induced exfoliative dermatitis in a Saudi patient with deck chair sign
N Banka et al.
DERMATOLOGY (2003)
STI571-induced Stevens-Johnson syndrome
D Vidal et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia
M Schwarz et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2002)
Imatinib mesylate and gray hair
G Etienne et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Improvement of psoriasis during imatinib therapy in a patient with a metastatic gastrointestinal stromal tumour
S Miyagawa et al.
BRITISH JOURNAL OF DERMATOLOGY (2002)
Stevens-Johnson syndrome after treatment with STI571: a case report
LT Hsiao et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.
H Kantarjian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Pityriasis rosea associated with imatinib (STI571,Gleevec)
K Konstantopoulos et al.
DERMATOLOGY (2002)
Cutaneous reactions to STI571
M Brouard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Acute generalized exanthematous pustulosis associated with STI571 in a patient with chronic myeloid leukemia
MC Brouard et al.
DERMATOLOGY (2001)
Share Paper
